Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have received a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $8.75.

A number of research firms have weighed in on PYXS. Leerink Partners decreased their price target on shares of Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating on the stock in a research note on Thursday, July 2nd. HC Wainwright increased their price objective on shares of Pyxis Oncology from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pyxis Oncology in a report on Friday, September 25th. Wedbush lifted their target price on shares of Pyxis Oncology from $6.00 to $8.00 and gave the company an “outperform” rating in a research report on Thursday, September 10th. Finally, Wells Fargo & Company upped their target price on shares of Pyxis Oncology from $12.00 to $19.00 and gave the company an “overweight” rating in a research note on Wednesday, September 9th.

Pyxis Oncology Trading Down 1.0%

Shares of PYXS stock opened at $1.99 on Friday. Pyxis Oncology has a 12 month low of $1.03 and a 12 month high of $5.55. The company has a market capitalization of $165.99 million, a P/E ratio of -1.41 and a beta of 1.37. The stock has a 50 day moving average of $3.11 and a two-hundred day moving average of $2.42.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Sell-side analysts predict that Pyxis Oncology will post -1.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pyxis Oncology

Institutional investors have recently added to or reduced their stakes in the stock. J. Derek Lewis & Associates Inc. bought a new stake in Pyxis Oncology during the 4th quarter worth approximately $61,000. Renaissance Technologies LLC increased its holdings in Pyxis Oncology by 22.0% during the 1st quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock valued at $1,297,000 after purchasing an additional 160,300 shares in the last quarter. Finally, 683 Capital Management LLC raised its position in Pyxis Oncology by 69.9% in the 4th quarter. 683 Capital Management LLC now owns 891,910 shares of the company’s stock valued at $1,026,000 after purchasing an additional 366,910 shares during the last quarter. 39.07% of the stock is owned by institutional investors and hedge funds.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc (NASDAQ: PYXS) is a clinical-stage biotechnology company developing therapies for cancer. The company focuses on treatments designed to address both tumor cells and the tumor microenvironment, with the goal of improving the effectiveness of the immune system and other anticancer mechanisms against solid tumors.

Its research and development programs include antibody-drug conjugates and immunotherapies. Pyxis Oncology’s lead program, PYX-201, is an antibody-drug conjugate designed to target the extradomain B form of fibronectin, a protein found in the tumor microenvironment, and deliver an anticancer payload to tumor tissue.